Periphere arterielle Verschlusskrankheit

Die periphere arterielle Verschlusskrankheit (pAVK) ist eine chronische Gefäßerkrankung, die durch atherosklerotische Veränderungen der peripheren Arterien verursacht ist. Sie führt zu Durchblutungsstörungen, insbesondere in den Extremitäten, und ist mit erhöhter Morbidität und Mortalität assoziiert. Der Beitrag stellt das diagnostische und therapeutische Management vor.

Schlüsselwörter

Extremitätenischämie - Gefäßerkrankung - Diabetes mellitus - Antikoagulation

Keywords

limb ischaemia - vascular disease - diabetes mellitus - anticoagulation

• Literatur

• 1 Schünke M, Schulte E, Schumacher U. Prometheus. LernAtlas der Anatomie. Allgemeine Anatomie und Bewegungssystem. Illustrationen von M. Voll und K. Wesker. 6. Stuttgart: Thieme; 2022
• 2 Taylor GI, Palmer JH. The vascular territories (angiosomes) of the body: experimental study and clinical applications. Br J Plast Surg 1987; 40: 113-141
• 3 Schillinger M, Sabeti S, Loewe C. et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Eng J Med 2006; 354: 1879-1888
• 4 Debus ES, Gross-Fengels W. Operative und interventionelle Gefäßmedizin. 2. Berlin, Heidelberg: Springer; 2020
• 5 Norgren L, Hiatt WR, Dormandy I. TASC II, Working Group. et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl. 01) 1-75
• 6 Deutsche Gesellschaft für Angiologie – Gesellschaft für Gefäßmedizin e. V. (DGA). S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. AWMF Registernmmer: 065–003. Zugriff am 06. Dezember 2024 unter: https://register.awmf.org/de/leitlinien/detail/065-003
• 7 Tuncer O, Du Y, Michalski N. et al. Diabetesbedingte Amputationen in Deutschland im Trend 2015–2022 und nach sozialräumlicher Lage. Robert Koch Institut. J Health Monit 2024; 9: 1-6
• 8 Duff S, Mafilios MS, Bhounsule P. et al. The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag 2019; 15: 187-208
• 9 Diener H, Larena A, Köbel T. et al. Revaskulation und Amputation bei kritischer Ischämie. Gefäßchirurgie 2010; 15: 20-32
• 10 Nordanstig J, Behrendt CA, Baumgartner I. et al. Editor’s Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg 2024; 67: 9-96
• 11 Aboyans V, Ricco JB, Bartelink MEL. et al. Editor’s Choice – 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg 2018; 55: 305-368
• 12 Steffel J, Eikelboom JW, Anand S. et al. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus asppirin as compared with aspirin in patients with chronic vascular disease. Circulation 2020; 142: 40-48
• 13 Bavry AA. Vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease – VOYAGER PAD. American College of Cardiology. 2023 Zugriff am 06. Dezember 2024 unter: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2020/03/26/19/48/VOYAGER-PAD
• 14 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994-2004
• 15 Canonico ME, Wang CCL, Hsia J. et al. Low-dose rivaroxaban plus aspirin in fragile patients after lower extremity revascularization. J Am Coll Cardiol 2024; 84: 801-811
• 16 Blessing E. [Update peripheral arterial occlusive disease]. Herz 2015; 40: 1013-1022
• 17 Zeller T, Giannopoulos S, Brodmann M. et al. Orbital atherectomy prior to drug-coated balloon angioplasty in calcified infrapopliteal lesions: a randomized, multicenter pilot study. J Endovasc Ther 2022; 29: 874-884
• 18 Patel MR, Conte MS, Cutlip DE. et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol 2015; 65: 931-941
• 19 Werner M, Paetzold A, Banning-Eichenseer U. et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention 2014; 10: 861-868
• 20 Dake MD, Ansel GM, Jaff MR. et al. Sustained safety and effectiveness of placitaxel-eluting stents for femoropopliteal lesions: 2-year follow up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013; 61: 2417-2427
• 21 Duda SH, Bosiers M, Lammer J. et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006; 13: 701-710
• 22 Klumb C, Lehmann T, Aschenbach R. et al. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: A systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine 2019; 16: 42-50
• 23 Bosiers M, Deloose K, Callaert J. et al. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial. J Endovasc Ther 2015; 22: 1-10
• 24 Dippel EJ, Makam P, Kovach R. et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv 2015; 8: 92-101
• 25 Bhatt DL, Steg PG, Ohman EM. et al. International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189
• 26 Farber A, Menard MT, Conte MS. et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Eng J Med 2022; 387: 2305-2316
• 27 Bradbury AW, Hall J, Moakes CA. et al. Bypass versus angioplasty for severe ischemia of the leg (BASIL)-2 trial: analysis oft he timing and causes of death in participants randomised to an infrapopliteal vein bypass or best endovascular treatment first revascularization strategy. Eur J Vasc Endovasc Surg 2024; 26
• 28 Yan Q, Prasla S, Carlisle DC. et al. Deep venous arterialization for chronic limb threatening ischemia in atherosclerosis patients – a meta-analysis. Ann Vasc Surg 2022; 81: 1-21
• 29 Debus ES, Grundmann RT. Evidenzbasierte Gefäßchirurgie. Leitlinien und Studienlage. 3. Berlin, Heidelberg: Springer; 2022
• 30 Shishehbor MH, Powell RJ, Montero-Baker MF. et al. Transcatheter arterialization of deep veins in chronic limb-threatening ischemia. N Engl J Med 2023; 388: 1171-1180